Celebrex Needs To Prove GI Safety Advantage Over Ibuprofen - HRG's Wolfe
Executive Summary
Searle/Pfizer's Celebrex should not be able to claim increased gastrointestinal safety over other NSAIDs until a clear safety advantage over ibuprofen is proven, Public Citizen's Health Research Group Director Sidney Wolfe, MD, told FDA's Arthritis Drugs Advisory Committee meeting on celecoxib Dec. 1.